Shahana Parveen1, Dhivya Bharathi Saravanan1, Rohit Saluja2,3, Berla Thangam Elden1. 1. Department of Biotechnology, School of Bio-Engineering, SRM Institute of Science and Technology, Chennai, India. 2. Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India. 3. Department of Biochemistry, All India Institute of Medical Sciences, Bibinagar, India.
Abstract
Context: IL-33 is a pro-inflammatory cytokine that is involved in the development of chronic inflammatory diseases and the initiation of allergic inflammation in response to pathogens and acts an alarmin.Objective: Present study aims to explore the IL-33 mediated effects of histamine induced allergic inflammation in human mast cells.Materials and methods: In this study, cord blood derived CD34+ mast cells and HMC-1 cells were primed with IL-33 followed by the stimulation with histamine. We investigated the functional activation of mast cell by intracellular calcium release using calcium mobilization assay, release of granular content using degranulation assay, profiling of various inflammatory and regulatory cytokines as well as chemokines by Luminex Bioplex assay and its signaling mechanisms involved using western blot analysis. Results: In our study, we found that the IL-33 acts as a mediator in the allergic inflammation induced by the histamine. IL-33 potentiates the release of intracellular calcium and degranulation content in human mast cells. Also, it enhances the production of Th2, Th1 cytokines and chemokines and down-regulates the production of regulatory cytokine. Furthermore, it enhanced the phosphorylation of the signaling molecules such as ERK, Akt, and NFκB in activated mast cells. Therefore, IL-33 acts as a potent activator of mast cells and it can elicit inflammatory response synergistically with histamine.Conclusions: Taken together, IL-33 acts as a potent mediator by inducing the inflammatory response in activated mast cells, hence increasing their responsiveness to antigens and amplifying the allergic response.
Context:IL-33 is a pro-inflammatory cytokine that is involved in the development of chronic inflammatory diseases and the initiation of allergic inflammation in response to pathogens and acts an alarmin.Objective: Present study aims to explore the IL-33 mediated effects of histamine induced allergic inflammation in human mast cells.Materials and methods: In this study, cord blood derived CD34+ mast cells and HMC-1 cells were primed with IL-33 followed by the stimulation with histamine. We investigated the functional activation of mast cell by intracellular calcium release using calcium mobilization assay, release of granular content using degranulation assay, profiling of various inflammatory and regulatory cytokines as well as chemokines by Luminex Bioplex assay and its signaling mechanisms involved using western blot analysis. Results: In our study, we found that the IL-33 acts as a mediator in the allergic inflammation induced by the histamine. IL-33 potentiates the release of intracellular calcium and degranulation content in human mast cells. Also, it enhances the production of Th2, Th1 cytokines and chemokines and down-regulates the production of regulatory cytokine. Furthermore, it enhanced the phosphorylation of the signaling molecules such as ERK, Akt, and NFκB in activated mast cells. Therefore, IL-33 acts as a potent activator of mast cells and it can elicit inflammatory response synergistically with histamine.Conclusions: Taken together, IL-33 acts as a potent mediator by inducing the inflammatory response in activated mast cells, hence increasing their responsiveness to antigens and amplifying the allergic response.
Authors: Marcela T Taruselli; Elizabeth Motunrayo Kolawole; Amina Abdul Qayum; Tamara T Haque; Heather L Caslin; Daniel Abebayehu; Sydney A Kee; Jordan M Dailey; Kaitlyn G Jackson; Jason R Burchett; Andrew J Spence; Neha Pondicherry; Brian O Barnstein; Gregorio Gomez; David B Straus; John J Ryan Journal: Cell Immunol Date: 2021-11-24 Impact factor: 4.868
Authors: Peter W West; Rajia Bahri; Karen M Garcia-Rodriguez; Georgia Sweetland; Georgia Wileman; Rajesh Shah; Angeles Montero; Laura Rapley; Silvia Bulfone-Paus Journal: Front Immunol Date: 2021-02-01 Impact factor: 7.561
Authors: Marloes van Splunter; Liu Liu; R J Joost van Neerven; Harry J Wichers; Kasper A Hettinga; Nicolette W de Jong Journal: Nutrients Date: 2020-12-15 Impact factor: 5.717